S&P 500 7,745 -0.10% Nasdaq 26,645 +0.15% Dow Jones 53,460 -0.96% FTSE 100 10,720 -1.31% DAX 26,339 +0.06% Nikkei 225 67,636 +0.17% Hang Seng 25,450 -0.79% WTI Crude 85.09 +4.73% Gold 4,452 +2.02% US 10-Year Treasury Yield 4.724 +0.85% S&P 500 7,745 -0.10% Nasdaq 26,645 +0.15% Dow Jones 53,460 -0.96% FTSE 100 10,720 -1.31% DAX 26,339 +0.06% Nikkei 225 67,636 +0.17% Hang Seng 25,450 -0.79% WTI Crude 85.09 +4.73% Gold 4,452 +2.02% US 10-Year Treasury Yield 4.724 +0.85%

LATEST

Wells Fargo resets its inflation target for 2026 and 2027●Chinese commercial banks gain margin relief, but subdued lending dims outlook●The bitcoin price level where leveraged bulls could get whacked●Food inflation hits 20.31% in July 2026, highest since September 2025●Dun Tianrui wants to take wind power into the sky●NSE begins valuation exercise for mega-IPO after strong institutional demand during roadshows●AI-enabled breaches push average damage cost to $6.04m as Digital Encode launches autonomous cybersecurity platform●Mukul Agrawal-backed PTC Industries shares slip 4% despite 466% surge in Q1 profit and 180% EBITDA growth●Wells Fargo resets its inflation target for 2026 and 2027●Chinese commercial banks gain margin relief, but subdued lending dims outlook●The bitcoin price level where leveraged bulls could get whacked●Food inflation hits 20.31% in July 2026, highest since September 2025●Dun Tianrui wants to take wind power into the sky●NSE begins valuation exercise for mega-IPO after strong institutional demand during roadshows●AI-enabled breaches push average damage cost to $6.04m as Digital Encode launches autonomous cybersecurity platform●Mukul Agrawal-backed PTC Industries shares slip 4% despite 466% surge in Q1 profit and 180% EBITDA growth●

Asia

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness

Markets-Economic Times · 2h ago · 🇮🇳 India

Lupin shares in focus after USFDA nod for drug to treat excessive daytime sleepiness

Lupin received USFDA approval for generic Pitolisant Tablets, strengthening its US portfolio and specialty generics presence. Shares remain technically weak despite strong long-term returns, with FIIs raising their stake while mutual fund holdings declined. The stock trades below most key moving averages, keeping near-term momentum subdued despite the positive regulatory development.

Read the full story at Markets-Economic Times →

More Asia

Chinese commercial banks gain margin relief, but subdued lending dims outlook

Business - South China Morning Post · 10m ago

NSE begins valuation exercise for mega-IPO after strong institutional demand during roadshows

mint - markets · 23m ago

Mukul Agrawal-backed PTC Industries shares slip 4% despite 466% surge in Q1 profit and 180% EBITDA growth

Markets-Economic Times · 29m ago

NSE to seek up to Rs 5.26 lakh crore valuation in record IPO: Report

Markets-Economic Times · 37m ago